EOLS
What one share of Evolus holds
Pharmaceutical Preparations
We are a global performance beauty company delivering breakthrough products with a customer-centric approach. Our primary market is the cash-pay aesthetic market, which consists of medical products that consumers pay for directly out of pocket.
Evolus’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $4.85 |
|---|---|
| Profit | −$0.53 |
| Capex (buildings and equipment) | $0.04 |
| Free cash flow | −$0.28 |
| Cash and investments | $0.68 |
| Debt | $2.37 |
| Book value | −$0.47 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$0.27 | $0.00 | −$0.80 | — | −$4.57 |
| 2018 | $0.00 | −$1.92 | $0.00 | −$1.05 | — | $3.09 |
| 2019 | $1.24 | −$3.19 | $0.01 | −$3.32 | — | $2.37 |
| 2020 | $1.68 | −$4.83 | $0.02 | −$1.74 | — | −$2.16 |
| 2021 | $2.00 | −$0.94 | $0.01 | −$0.68 | — | $1.47 |
| 2022 | $2.65 | −$1.33 | $0.03 | −$1.54 | — | $0.33 |
| 2023 | $3.55 | −$1.08 | $0.01 | −$0.61 | — | −$0.36 |
| 2024 | $4.29 | −$0.81 | $0.02 | −$0.31 | — | $0.09 |
| 2025 | $4.61 | −$0.80 | $0.05 | −$0.71 | — | −$0.36 |